Shanghai Pharmaceuticals Holding
Shanghai Pharmaceuticals Holding Co., Ltd. is a Chinese state-owned pharmaceutical enterprise that researches, manufactures, distributes, and retails prescription drugs and healthcare products across China. The company operates through four primary business segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Other Operations. Its principal revenue drivers consist of wholesale pharmaceutical distribution sales to domestic hospitals, commercial sales of self-manufactured cardiovascular and oncology drugs, and retail pharmacy sales. Shanghai Pharmaceuticals holds a leading position as China's second-largest pharmaceutical distributor and a major drug manufacturer, operating an integrated supply chain reaching all Chinese provinces. The enterprise caters to public hospitals, retail pharmacy networks, medical providers, and patients nationwide. The company focuses on expanding R&D for innovative oncology biologics, broadening pharmaceutical distribution logistics, acquiring international biopharmaceutical assets, and digitizing retail pharmacy operations. Shanghai Pharmaceuticals Holding Co., Ltd. is headquartered in Shanghai, China, and its shares are publicly listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange.
9 of the funds FundTelligence covers report a position in Shanghai Pharmaceuticals Holding.
- Legal name
- Shanghai Pharmaceuticals Holding Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 9
Funds holding Shanghai Pharmaceuticals Holding
- KLP AksjeFremvoksende Markeder Flerfaktor — KLP · 0.52 % (full portfolio disclosed, June 2026)
- Nordea Stable Emerging Markets — Nordea Funds · 0.29 % (full portfolio disclosed, July 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Emerging Markets — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.0 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 9 funds holding it.